Sharada V. Kolekar
Auckland, AUK, New Zealand
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models.
Journal: Molecular cancer therapeutics
Published: November 21, 2021
Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Journal: BMC cancer
Published: September 10, 2020
Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma.
Journal: Pigment cell & melanoma research
Published: May 11, 2020
A core outcome set for future endometriosis research: an international consensus development study.
Journal: BJOG : an international journal of obstetrics and gynaecology
Published: January 28, 2020
Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.
Journal: Oncotarget
Published: January 31, 2017
Novel pyrazolo[1,5-a]pyridines with improved aqueous solubility as p110α-selective PI3 kinase inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: November 03, 2016
Exploring the isoform selectivity of TGX-221 related pyrido[1,2-a]pyrimidinone-based Class IA PI 3-kinase inhibitors: synthesis, biological evaluation and molecular modelling.
Journal: Bioorganic & medicinal chemistry
Published: January 08, 2015
Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
Journal: European journal of medicinal chemistry
Published: September 27, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026